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Atypical lymphoproliferation progressing into B-cell
lymphoma in rheumatoid arthritis treated with
different biological agents: clinical course and
molecular characterization
Rheumatoid arthritis (RA) is a well-recog-nized condition predisposing to malig-nant lymphoma, usually a B-cell non-
Hodgkin’s lymphoma (NHL).1-5 B cells play a
crucial role at least in some subsets of RA
patients,6-8 and both chronic inflammation and
ongoing antigenic B-cell stimulation related to
the disease may favor the stochastic emergence
of a neoplastic B-cell clone.9,10 The molecular
evidence of chronic antigenic B-cell stimulation
in RA and the increased incidence of NHL in
patients with RA of longer duration support
this notion.1-5 Chronic immunosuppression due
to RA therapy, leading to loss of immunosur-
veillance, might also play a role.11 Treatment
options that may be effective on RA without
favoring B-cell expansion should be better
defined.6,7 We report the clinical course of a
patient with RA who developed a non-malig-
nant atypical lymphoproliferative disorder
(LPD)12 which then progressed into an aggres-
sive B-cell NHL, and discuss the case with ref-
erence to the different immunosuppressive and
biological treatments employed. In addition,
the B-cell disorder was characterized by molec-
ular studies, which supported our data interpre-
tation and shed some light on possible similar-
ities between lymphoproliferation in RA,
Sjögren’s syndrome and mixed cryoglobuline-
mia syndrome.13
Design and Methods
Clinical data
A 77-year old woman was admitted to our
Clinic in October 1999 with fever, sweating,
axillary lymphadenopathy and splenomegaly.
She had been affected by rheumatoid factor
(RF)-positive RA since 1949. The patient had
been treated with steroids for many years, then
with methotrexate. In June 1999 cyclosp-
sporine A (2.5 mg/kg/day) was combined with
methotrexate (15 mg/week). The patient did
not have Sjögren’s syndrome or mixed cryo-
globulinemia syndrome and was negative for
hepatitis B and C virus (HCV) infection. In
October 1999 her lactate dehydrogenase (LDH)
increased and a computed tomography scan
(CT) demonstrated multiple enlarged lymph
nodes in the mediastinum and retroperi-
toneum, splenomegaly and hepatomegaly.
Nodal biopsy showed an atypical LPD (Figure
1). Variable, diversity and joining (V-D-J) region
rearrangements of tissue immunoglobulin
heavy chain amplified by polymerase chain
reaction (PCR)9 showed an oligoclonal pattern
of B-cell expansion, while the Epstein Barr virus
was not detected by PCR or in situ hybridiza-
tion. The bone marrow was uninvolved.
Methotrexate was stopped in March 2000
without improvement. Then, cyclosporine A
was stopped and methotrexate was reintro-
duced since the woman’s synovitis had wors-
ened; again there were no improvements in
LPD manifestations. In January 2001 a second
nodal biopsy showed unchanged histopatho-
logical features. Methotrexate was then inter-
rupted and the LPD completely regressed by
March 2001 as shown by physical examination
and by negative chest X-rays and ultrasound of
the abdomen. However, the patient’s arthritis
was still very active. Chloroquine and sul-
phasalazine were ineffective. In August 2001
repeated CT demonstrated normally sized
spleen and liver, and lymph nodes sized less
than 1 cm in the mediastinum and retroperi-
toneum. The patient then underwent four
intravenous weekly infusions of rituximab (375
mg/m2): RA responded,6 RF became negative,
and features of LPD were absent. In January
2002 the patient’s RA relapsed, but a second
course of rituximab could not be repeated
because of its high costs. Leflunomide was not
tolerated. Etanercept 25 mg twice weekly was
started in April 2003. A total-body CT repeated
at that time was unchanged compared to that
performed in August 2001. In November 2003
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Lymphoproliferative Disorders • Brief Report
A patient with rheumatoid arthritis (RA) developed an atypical lymphoproliferative disorder (LPD)
after methotrexate and cyclosporine A, which regressed after suspension of both drugs. After
subsequent treatment with rituximab, the LPD was still undetectable. Anti-tumor necrosis factor
α therapy was used when the arthritis relapsed, but an aggressive B-cell non Hodgkin’s lym-
phoma developed. Molecular analyses showed an oligoclonal B-cell expansion at the LPD step.
A minor clone with significant sequence homology to B-cell lymphomas arising in Sjögren’s syn-
drome and mixed cryoglobulinemia syndrome, given rise to the non-Hodgkin’s lymphoma.
Treatment of rheumatoid arthritis associated with lymphoproliferation represents a clinical chal-
lenge, and common pathogenetic pathways to lymphoma may occur in different autoimmune dis-
eases.  
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the patient developed fever, fatigue and itching, and
increased LDH, while her RA was well controlled. A total-
body CT showed several enlarged thoracic and abdominal
lymph nodes and an abdominal nodal mass of 12×8 cm; the
needle biopsy of this mass demonstrated a diffuse large B-
cell NHL.14 The bone marrow was uninvolved. 
Molecular studies
DNA from the LPD specimens taken in June 1999
(LPD99) and January 2001 (LPD01) were amplified by PCR
using the seminested heavy chain V-D-J-third framework
region (FR3) protocol,8 revealing an oligoclonal (LPD99)
and a polyclonal (LPD01) pattern of B-cell expansion, while
the neoplastic abdominal mass (NHL04) showed a fully
monoclonal pattern. The oligoclonal bands of the LPD99
FR3-PCR and the monoclonal band of the NHL04 FR3-
PCR products were purified and cloned in a bacterial vec-
tor (TOPO-TA cloning kit, Invitrogen). Sixteen colonies,
chosen at random, for the LPD99 and seven colonies for
the NHL04 FR3-PCR products were sequenced (Table 1).
Strikingly, the seven sequences of the neoplastic B-cell
clone (NHL04-1) were nearly identical to those of a minor
clone of the LPD99 lesion  (LPD99-6 clone)  (Table 1 and
Figure 2). To identify the VH genes of the neoplastic clone,
multiple PCR were prepared, each containing a forward
primer specific for the FR1 region of each of the VH fami-
lies (VH1 to VH6) and a reverse primer consisting of a mix-
ture of JH primers.15 The VH1 family was used by the neo-
plastic B-cell clone. The whole PCR product was cloned
and sequenced, and then different clone-specific PCR
approaches (with primers designed on the NHL04
sequence; data not shown) confirmed that the clone giving
rise to the lymphoma was already present in the preneo-
plastic LPD99 lymph node biopsy (LPD99-6 clone) (Figure
2), while it was undetectable in the LPD01 polyclonal spec-
imen, as well as in both peripheral blood and bone marrow
mononuclear cells obtained at the time of lymphoma diag-
nosis. The NHL04 B-cell clone sequences were compared,
using the V-QUEST program, with the germline genes in
the IMGT directory. The best fitting germline sequence
was IGHV1-69*01. Similarly, the rearranged light chain
gene was amplified,13 cloned and sequenced revealing its
best fit with the IGKV3-20*01 germline sequence. A multi-
Figure 1. Nodal atypical
lymphoproliferative dis-
order of the reported
case. A. Low power view
of the LPD99 lymph
node biopsy, showing a
follicle and a markedly
expanded paracortical
area, rich in high
endothelial venules
(H&E, 10×). B. High
power view of the para-
cortical area of the
same biopsy: a few
small lymphocytes with
irregular nuclei are evi-
dent among an expand-
ed lymphoid prolifera-
tion of large cells with B
morphology (centrocytic
cells, centroblasts, occa-
sional immunoblasts).
Many mitoses are evi-
dent (H&E, 40×).
A
B
Table 1. Nucleotide and deduced amino acid sequences of the cloned FR3-PCR products obtained by the amplification of the DNA from
the nodal specimens LPD99 and NHL04. The putative specificity of each CDR3-IgH sequence was found by submitting the deduced
amino acid sequence in the Translate BLAST search protein program (http://www.ncbi.nlm.nih.gov/blast/) considering the first five best
fitting alignments characterized by higher values of homology (>80- 90%). 
Subclone N° of Sequence Translation Putative
name identical activity
colonies
LPD99-1 3 5’-ACACGGCTGTATTACTGTGCACGGCAAA TALYYCARQ Autoimmune
GTAGTGGTTATTACTACTCGTTATCAAGGGTACTGGTTCGACCC SSGYYYSLSR repertoire
CTGGGGCCAAGGCACCCTGGTCAC-3’ VLVRPLGPR HPGH (MG, SLE)
LPD99-2 2 5’-ACACGGCTCTGTATTACTGTGGGAGAAGT TRLCITVGEV Human Ig unspecified
TATGGTTCGGGGAGTTATGGAGTTGACTACTGGGCCAA MVRGVMEL
GGCACCCTGGTCA-3’ TTGAKAPWS
LPD99-3 3 5’- ACACGGCTCTGTATTACTGTGCGAGGCTTC TALYYCARL Ig produced 
TTTCGGAGGCTGAGGGATACTTTGACTACTG LSEAEGYFD by synovial B cells
GGGCCAAGGCACCCTGGTCAC-3’ YGQGTLV
LPD99-4 6 5’-ACACGGCTCTGTATTACTGTGCGAGAGTG TALYYCARV Human
GGGTGGATAGAAGCAGCGGGGGGCGTTAACT GWIEAAGGV unspecified
ACTGGGGCCAAGGCACCCTGGTCAC-3’ NYWGQGTLV
LPD99-5 1 5’- ACACGGCTCTGTATTACTGTGCGAGAGATC TALYYCARD Autoimmune 
TTTTCTGTTTGAGTATAGCAGTGGCTGGTCCGA LFCLSIAVA#S repertoire (aCL)
CTACTGGGGCCAAGGCACCCTGGTCAC -3’
LPD99-6 1 5’-ACACGGCTCATGTATTACTGTGCGAGAGAG TAMLYYCAR RF*
GGGAGGCAGATGGCTTCAAACCCCTTTGACT EGRQMASNP
ACTGGGGCCAAGGCACCCTGGTCAC-3’ FDYWGQGTLV
NHL04 7 5’-ACACGGCTACTGTATTACTGTGCGAGAGA TAMLYYCAR RF°
AGGGAGGCAGATGGCTACAAACCCGTTTGACT EGRQMATNP
ACTGGGGCCAAGGCACCCTGGTCAC-3’ FDYWGQGTLV
MG: myasthenia gravis; SLE, systemic lupus erythematosus; aCL, anticardiolipin antibody. *Detailed analysis revealed that the clone NHL04 (seven identical sequences)
was already present at the stage of the LPD99 (see text and Figure 1). The nucleotide alignment between the FR3-JH regions of the LPD99-6 and NHL04 clone revealed two
silent and one replacement mutation in the latter. The replacement mutation was Ser in LPD99-6 to Thr in NHL04.°Submission of the sequences to the Translate BLAST
search protein program revealed a high homology with the following RF: 1) gi|225800|prf||1313976A: Rheumatoid factor BOR [Score: 86.3 bits (196), Expect: 7e-17;
Identities: 25/27 (92%), Positives: 26/27 (96%)];  2) gi|510402|emb|CAA84416.1|: IgM, variable region, rheumatoid factor, autoantibody- Homo sapiens;
[Score: 77.0 bits (174), Expect: 5e-14 Identities: 22/26 (84%), Positives: 25/26 (96%)].
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nomial distribution model16 assessed the statistical signifi-
cance of an excess or scarcity of replacement mutations in
complementarity determining regions and framework
regions  (www.stat.stanford.edu/immunoglobulin). The replace-
ment/silent mutation ratio showed a lower than expected
value only in the framework regions (p=0.04) of the IGH
sequence, consistent with the preservation of
immunoglobulin (Ig) functional structure, while the ratios
of the complementarity determining regions of both VH
and VK and the framework regions of VK were not signif-
icantly different from the expected value. Very limited intr-
aclonal heterogeneity was found among the different sub-
clones (six subclones for IgH, with 5/6 identical sequences
named NHL04-1; and 12 subclones for IgK, with 6/12 iden-
tical sequences named NHL04-1k), as expected in aggres-
sive NHL (data not shown). Submission of the NHL04 clone
heavy and light chain gene sequences to IgBLAST showed
a significant similarity to the Ig gene sequence of LPD
occurring in other autoimmune diseases predisposing to
lymphoma, i.e., Sjögren’s syndrome and mixed cryoglo-
binemia syndrome (Figure 2), in which RF-binding activity
of the proliferating clone has also been demonstrated by
functional studies.17,18 To investigate the reactivity of the
tumor immunoglobulin we employed in vitro generated
antibodies identical to those produced by lymphoma cells.
The Ig VH and VK rearrangements of lymphoma were
amplified, cloned and expressed as single chain fragment
variable (scFv) antibody. For this purpose the Ig-VH and
VK genes (dominant sequences) of case NHL04 were
cloned into the pIVEX 2.4c vector (Roche) that contains the
coding sequence for the (G4S)3 peptide linker for joining the
heavy and light chains and a His-tag. For complete in vitro
expression of scFv, the rapid translation system (RTS 100
Escherichia coli HY; Roche), which constitutively expresses
the reporter gene from a T7 promoter, was used. The gene
product was purified by affinity, then identified and quan-
tified by autoradiography following SDS–PAGE. Using an
ELISA assay, no RF reactivity was found for scFv (data not
shown).
Results and Discussion
In this report we highlight the possible different safety
profiles of various biological treatments in a patient with
RA and an associated B-cell non-malignant LPD. A strict
genetic similarity between RA-related lymphoma and
lymphomas related to Sjögren’s syndrome and mixed
cryoglobulinemia syndrome is reported for the first time,
suggesting a possible common pathogenetic pathway. Risk
factors for NHL development in RA include a higher
inflammatory activity, functional class and advancing age,4
consistent with the concept that chronic inflammation
associated with ongoing B-cell proliferation may favor sto-
chastic B-cell oncogenetic events.9 While effective
immunosuppressive treatments for RA may reduce the
risk of lymphoproliferation by blocking RA-related chron-
ic inflammation, they may also favor the escape of dereg-
ulated B-cell clones.  Rituximab therapy proved of value in
the patient described here, since it allowed RA control
without favoring (and indeed possibly controlling) B-cell
lymphoproliferation. Of note, the B-cell clone subsequent-
ly evolving into the aggressive B-cell NHL was present in
the non-neoplastic, oligoclonal LPD previously diagnosed
in 1999. It was not detected in a second, polyclonal LPD
lesion biopsied two years later in a different nodal site,
consistent with a definitely non-malignant B-cell disorder
characterized by the expansion of different B-cell clones in
different lesions.12 Although cyclosporine A rather than
methotrexate administration has been related to the emer-
gence of lymphoproliferative disorders in a few RA cases,
and has been closely related to post-transplantation LPD,
the LPD lesion in our case regressed only after suspension
of both the immunosuppressive agents. LPD also remained
undetectable after rituximab therapy. The link between
anti-tumor necrosis factor-α (TNFα) therapy and the risk
of NHL development in RA is still debated.3-5 Although the
literature does not clearly support a role for anti-TNFα
therapy in B-cell lymphomagenesis in RA in general, such
a role may be hypothesized in single cases. As concerns
Figure 2. The deduced amino acid sequences of the heavy
(panel A) and light (panel B) chain variable regions of NHL04-
1 and LPD99-6 samples are reported (only the heavy chain
was analyzed for LPD99-6), in conjunction with the most sim-
ilar database sequences. All the sequences employed the
VH1-69 and VK3.20 genes, corresponding to the germline V1-
69 and A27 amino acid sequences shown. The number of the
corresponding NCBI genbank sequence is indicated in paren-
theses. The light gene sequences of RF-mixed cryoglobuline-
mia type II (MCII) (a and b clones) and RF-Sjögren’s syndrome
(SS) belong to the corresponding clone in panel A. All these
database sequences encoded RF. The VK sequence and anti-
body specificity of the sequence RF-donor is not known.
Identical amino acids are reported by dashes, amino acid
substitutions with conserved physico-chemical properties are
reported by ":", semi-conserved substitutions are reported by
“.”, while a blank space indicates completely different amino
acids. Changes in the LPD99-6 and NHL04-1 sequences with
respect to germline are evidenced in gray. Alignment of the
NHL04-1 and LPD99-6 sequences shows that ten identical
amino acid substitutions are shared, consistent with the com-
mon origin from the same progenitor clone; one additional
amino acid change in the CDR3 region (one substitution of
Ser to Thr, reported in bold and underlined; see also Table 1)
is present in the NHL04-1 clone. 
A
B
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our patient, there was a clear temporal relationship
between anti-TNFα therapy and lymphoma development.
Recently, the protective role of TNFα against NHL evolu-
tion was demonstrated in the murine model of TNF-/- B-cell
activating factor (BAFF) transgenic mice.19 Therefore, TNFα
blockade may be not advisable when lymphoma is sus-
pected in RA. To our knowledge, no data have been pub-
lished so far on the antigen specificity of neoplastic B-cell
clones in RA. In our case, the clone giving rise to the B-cell
NHL was a minor clone detectable in one of the two
methachronous nodal biopsies at the pre-neoplastic stage
of LPD. The possibility that the homology between the
LPD-99 clone and the NHL clone is the result of chance is
highly unlikely, since sequence homology was almost
complete, and ten common amino acid substitutions were
noted (Figure 2). Strikingly, both the heavy and light chain
gene sequences of the tumor clone showed a significant
similarity with lymphoproliferation occurring in Sjögren’s
syndrome and mixed cryoglobulinemia syndrome. The
RF-binding activity of the proliferating clone has been
demonstrated by functional studies,17,18,20 in the latter dis-
eases. A significant homology with RF sequences was also
detected in the case reported here (Table 1), but functional
studies with scFv technology did not confirm such anti-
body specificity. It may be hypothesized that a similar sub-
set of B cells, i.e., employing a restricted pattern of Ig heavy
and light chain genes, may also be implicated in RA-relat-
ed lymphomagenesis, as in the two rheumatic diseases
with the highest risk of lymphoma evolution, Sjögren’s
syndrome and mixed cryoglobulinemia.8,9 The question of
whether RF-positive clones are preferentially involved in
RA-related lymphomagenesis remains unanswered. Even
in the lack of RF binding activity in the neoplastic clone
LPD04, RF activity may have characterized a progenitor
clone, with RF specificity then being lost due to somatic
mutations (Figure 2). Work is in progress in additional RA
lymphoma cases to address this issue. Alternatively, com-
mon antigenic epitopes might lead to the antigen-driven
proliferation15,17,20 and preferential expansion of a definite
subset of B cells, with some overlap with RF-encoding B-
cells. This is a key point for future research. In HCV-relat-
ed lymphoproliferation, reactivity of the proliferating B-
cell clone with HCV antigens has been shown,20 and our
preliminary data also support this possibility (De Re et al.,
in press). Thus, the definition of the antigen specificity of
the expanded clones in RA-related lymphomas may be rel-
evant to a better understanding of the etiology of the dis-
ease. In conclusion, treatment of RA associated with lym-
phoproliferation represents a clinical challenge. Our report
suggests that rituximab might prove of value in this set-
ting. The possible links between RA-associated lym-
phomagenesis and lymphoproliferation in Sjögren’s syn-
drome and mixed cryoglobulinemia syndrome8,13,15 should
be thoroughly investigated, and may provide new insights
in the etiopathogenesis of RA itself.
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